Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Richard L, Piekarz"'
Autor:
George E. Iliakis, Dian Wang, Richard L. Piekarz, Beverly A. Teicher, C. Norman Coleman, Mansoor Ahmed, Mohammad Sharif Mortoga Hasan, Shipra Chaudhary, Lisa Marie Krieger, Martha Grabos, You Wang, Fanghua Li, Aashish Soni
Table S1: Dose Modification Factor at 10% survival in different cell lines. Table S2: List of primary and secondary antibodies. Table S3: Cytotoxicity of different inhibitors in un-irradiated CHO cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b06a0cdca138f63a8bd84c47fc55eab
https://doi.org/10.1158/1535-7163.22505127.v1
https://doi.org/10.1158/1535-7163.22505127.v1
Autor:
George E. Iliakis, Dian Wang, Richard L. Piekarz, Beverly A. Teicher, C. Norman Coleman, Mansoor Ahmed, Mohammad Sharif Mortoga Hasan, Shipra Chaudhary, Lisa Marie Krieger, Martha Grabos, You Wang, Fanghua Li, Aashish Soni
(A) The DR-GFP reporter assay fails to detect an effect of BMN673. (B) BMN673 impairs DSB repair in human sarcoma and rhabdoid cell liines.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e45d1852ad4fecaa160ddad26fa3352
https://doi.org/10.1158/1535-7163.22505130.v1
https://doi.org/10.1158/1535-7163.22505130.v1
Autor:
George E. Iliakis, Dian Wang, Richard L. Piekarz, Beverly A. Teicher, C. Norman Coleman, Mansoor Ahmed, Mohammad Sharif Mortoga Hasan, Shipra Chaudhary, Lisa Marie Krieger, Martha Grabos, You Wang, Fanghua Li, Aashish Soni
Parp inhibitors (Parpi) are commonly used as single agents for the management of tumors with homologous recombination repair (HRR) deficiencies, but combination with radiotherapy (RT) is not widely considered due to the modest radiosensitization typi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c9e1192da83a04e62b5b3a9ad80489c
https://doi.org/10.1158/1535-7163.c.6537963.v1
https://doi.org/10.1158/1535-7163.c.6537963.v1
Autor:
Susan E. Bates, Richard L. Piekarz, William D. Figg, Seth M. Steinberg, Mark C. Haigney, Thomas P. Flagg, David J. Venzon, Tristan M. Sissung, David J. Liewehr, Robin A. Eisch, Anne M. Noonan
Supplementary Figure 3 - PDF file 62K, Changes in mean heart rate during cycles 1 when patients taking betablockers were excluded
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c09ac8e22e4be0770f1304d8a2f97f5
https://doi.org/10.1158/1078-0432.22450809.v1
https://doi.org/10.1158/1078-0432.22450809.v1
Autor:
Richard L. Piekarz, Susan E. Bates, Tito Fojo, William D. Figg, Monica Skarulis, John Wright, David Venzon, Sue Woo, Robin Frye, Deb Draper, James Reynolds, Kambiz Ghafourian, Cody J. Peer, Victoria Luchenko, Laleh Amiri-Kordestani
Supplementary Tables - PDF file 33K, Supplementary Table 1. Dose levels, dose administered on each treatment day, days 1,3, and 5 of a 21-day cycle, and number of patients treated on each dose level. Supplementary Table 2. Romidepsin toxicities found
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ade7b0319a628d926a54a4d23879983
https://doi.org/10.1158/1078-0432.22449377
https://doi.org/10.1158/1078-0432.22449377
Autor:
Susan E. Bates, Richard L. Piekarz, William D. Figg, Seth M. Steinberg, Mark C. Haigney, Thomas P. Flagg, David J. Venzon, Tristan M. Sissung, David J. Liewehr, Robin A. Eisch, Anne M. Noonan
Supplementary Figure 4 - PDF file 314K, Changes in mean heart rate during cycles 1 when patients taking betablockers were excluded
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01ca3a593269b84acd02e0d8b5f58a7a
https://doi.org/10.1158/1078-0432.22450806.v1
https://doi.org/10.1158/1078-0432.22450806.v1
Autor:
Susan E. Bates, Richard L. Piekarz, William D. Figg, Seth M. Steinberg, Mark C. Haigney, Thomas P. Flagg, David J. Venzon, Tristan M. Sissung, David J. Liewehr, Robin A. Eisch, Anne M. Noonan
Supplementary Figure 6 - PDF file 60K, Changes in heart rate observed for each patient in the NIH cohort during cycle 2 days 1, 8 and 15, excluding the patients taking beta-blockers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90ee3b87488980e69d40de4ba66736bc
https://doi.org/10.1158/1078-0432.22450800.v1
https://doi.org/10.1158/1078-0432.22450800.v1
Autor:
Richard L. Piekarz, Susan E. Bates, Tito Fojo, William D. Figg, Monica Skarulis, John Wright, David Venzon, Sue Woo, Robin Frye, Deb Draper, James Reynolds, Kambiz Ghafourian, Cody J. Peer, Victoria Luchenko, Laleh Amiri-Kordestani
Supplementary Figure 1 - PDF file 176K, Supplementary Figure 1: Comparison of dose-normalized CMAX (A) and AUCLAST (B) for the present phase I trial versus data obtained on the phase II NCI1312 trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51d5054b4723086189b3e1c13e2962fa
https://doi.org/10.1158/1078-0432.22449380
https://doi.org/10.1158/1078-0432.22449380
Autor:
Susan E. Bates, Tito Fojo, Seth M. Steinberg, Aradhana M. Venkatesan, Frank M. Balis, Erin R. Gardner, Xiaohong Chen, Richard L. Piekarz, William D. Figg, Robert W. Robey, Clara C. Chen, Deborah Draper, Ronan J. Kelly
Purpose: P-glycoprotein (Pgp) antagonists have been difficult to develop because of complex pharmacokinetic interactions and a failure to show meaningful results. Here we report the results of a pharmacokinetic and pharmacodynamic trial using a third
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c5869f3a1daaa7153fc7faa5db12807
https://doi.org/10.1158/1078-0432.c.6519969.v1
https://doi.org/10.1158/1078-0432.c.6519969.v1
Autor:
Susan E. Bates, Richard L. Piekarz, William D. Figg, Seth M. Steinberg, Mark C. Haigney, Thomas P. Flagg, David J. Venzon, Tristan M. Sissung, David J. Liewehr, Robin A. Eisch, Anne M. Noonan
Supplementary Figure Legends - PDF file 25K, Legends describing supplementary figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26983e175db6d2d1c0c9d409d03893c3
https://doi.org/10.1158/1078-0432.22450791
https://doi.org/10.1158/1078-0432.22450791